china ndrl underappreci
opportun keytruda
estim placement china nrdl could tripl keytruda
sale potenti decis could made
month coverag could start jan increas pt
maintain ow rate given
potenti growth upsid
nsclc alon could blockbust opportun keytruda estim
annual sale potenti nsclc alon keytruda without nrdl
placement nrdl placement assum negoti nrdl price
discount current list price china detail next section
base upon assumpt keytruda china nrdl nation reimburs
drug list price could lower us list price current keytruda
annual list price us china us list
price assum negoti nrdl price keytruda could
annual base averag histor discount pre-nrdl list price
china lung cancer drug list exhibit would
us list price merck comment estim
price china may caus investor constern keytruda secur
nrdl list expect investor express two concern low china
price low price could attract scrutini countri
risk countri includ china drug price refer price scheme
day china could pivot keytruda long-term order
drive price even support local
howev think volum opportun would off-set even
substanti discount price nrdl list would net posit
upsid consensu sale come year estim
new case lung cancer china annual could
theoret receiv keytruda nrdl believ repres
much larger market opportun especi sinc current net price includ
pap discount china could close nrdl price assumpt
understand lack reimburs limit sale keytruda
major pharmaceut unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
opdivo china date cancer drug china price fraction us
price exhibit keytruda unlik set new low bar price rel
us china could drive price longer term see
potenti new adjuv pre-metastat keytruda global indic dwarf
separ understand opdivo also candid nrdl
placement see modest sale potenti china opdivo opdivo
approv china egfr- alk- nsclc platinum chemo checkmate-
head neck cancer platinum chemo howev egfr-
nsclc popul much smaller china us vs
nsclc averag treatment durat shorter
addit potenti market opdivo would decreas time
keytruda ramp
increas pt increas pt
prior ep new ep
target multipl premium peer averag believ
justifi given strong growth prospect potenti upsid financi
surpris rais keytruda maintain
compound-annual-growth-rate revenue ep
pt base base case ep target multipl
premium peer averag believ justifi
given strong growth prospect potenti upsid surpris
bull case ep
bull case ep
keytruda surpris upsid drive earlier-than-expect margin
expans merck execut compel ep forecast due
higher-than-project keytruda sale drive oper leverag adjuv
base case ep
base case ep
merck deliv keytruda sale expect competitor lung cancer
trial match keytruda competitor trial result less inspir
keytruda keytruda adjuv trial offer option next
bear case ep
bear case ep
keytruda gardasil disappoint drive ep forecast
competitor io trial show surprisingli strong result rel keytruda
overweight merck base upon
compel long-term growth prospect
see upsid lt consensu driven
oncolog franchis gardasil cancer
pipelin option diseas beyond
oncolog come focu come
keytruda sale trend trial
immuno-oncolog news flow
extern busi develop
us ex-u price develop
competitor dataset newsflow
risk achiev price
upsid risk financi upsid clinic
shortfal compel strateg action
downsid risk financi shortfal key
disappoint drug price pressur
estim keytruda peak sale china could lung cancer
ad china nation reimburs drug list nrdl nrdl sale
estim assum discount current china list price per mg
dose alreadi lower us list price averag dose per
patient patient treat annual contrast keytruda ad
nrdl estim peak sale potenti keytruda lung cancer china would
roughli howev uncertain current net price china due
patient assist program potenti market share without nrdl list exhibit
exhibit
exhibit keytruda price china vs us
per dose usd
annual usd
exhibit estim keytruda sale potenti china privat market opportun rel
new case lung cancer
non-squam
annual usd
average durat treatment yr
pop w/o pap
pop w/ pap
note merck current offer buy first three dose get next three dose free patient assist program pap econom
swing factor assumpt estim discount merck would negoti
nrdl list potenti penetr given patient oop co-pay
understand manag care balanc china nrdl volum
opportun rel discount price intend negoti appropri
compani best near long term interest calcul assum discount
averag discount lung cancer drug ad nrdl
rang keytruda price would us list price
compar mean us list price lung cancer drug rang
exhibit merck secur nrdl list higher price would view
posit howev could somewhat off-set higher patient co-pay
possibl result lower penetr assumpt
exhibit price discount lung cancer drug follow ndrl inclus
lung cancer drug includ nrdl
keytruda pembrolizumab estimate
price discount
us list price
usd rmb
percent nsclc patient elig keytruda lower china us
due differ rate egfr mutat egfr mutat compris nsclc
china compar us alk countri keytruda
approv combin chemo egfr- alk- non-squam nsclc
april monotherapi egfr- alk- nsclc
octob keytruda approv indic china cover metastat
nsclc china significantli lower us two
indic asid keytruda approv squamou us yet
china nrdl would cover off-label indic
keytruda current approv therapi nsclc china
local competitor expect come year risk china could negoti
lower price merck local agent consid nrdl list
lung cancer howev merck manag expect govern respect
keytruda label differenti clinic dataset know six local agent
phase nsclc trial exhibit trial sponsor
hengrui cover sean wu innov biolog cover sean wu beigen
cover matthew harrison expect complet
exhibit phase nsclc trial china conduct chines manufactur
phase trial first therapi metastat nsclc
squamou
squamou
cisplatin carboplatin pemetrex
potenti implic keytruda nrdl inclus merck current offer
buy first three dose get next three dose free patient assist program
pap econom disadvantag patient understand privat market
price pap end keytruda ad nrdl patient would
expect pay out-of-pocket base upon nrdl price
new vs old ms vs consensu estim
exhibit incom statement margin valuat
sg sale
 sale
exhibit balanc sheet statement
short-term invest
a/p accru liabil
total liabil s/e
chang work capit
oper
invest
net chang debt
financ
net chang cash
act financi advisor bristol-my squibb compani bristol-
myer relat propos acquisit celgen corpor celgen
announc januari propos transact subject customari close
condit includ bristol-my celgen stockhold approv receipt
customari close condit regulatori approv report inform
provid herein intend provid vote advic ii serv endors
propos transact iii result procur withhold revoc
proxi action secur holder bristol-my agre pay fee
financi servic includ transact fee financ fee
conting upon consumm transact pleas refer note end
report
act financi advisor bristol-my squibb compani
relat agreement celgen corpor celgen inc
would acquir global right otezla apremilast
announc august transact pursuant merger agreement
celgen propos transact subject celgen
enter consent decre feder trade commiss connect
pend merger close pend merger satisfact customari
